About N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase
N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase (AGA) is a protein
from Homo sapiens identified by UniProt accession
P20933, 346 residues long.
MolForge cross-references it against 0 known binders and
192 disease associations.
Target properties
| Protein name | N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase |
| UniProt accession | P20933 |
| Gene | AGA |
| Organism | Homo sapiens |
| Length | 346 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (192)
Diseases linked to this target (Open Targets).
- aspartylglucosaminuria · score 0.84
- genetic disorder · score 0.49
- serum metabolite measurement · score 0.27
- asparagine measurement · score 0.27
- breast milk measurement · score 0.26
- self reported educational attainment · score 0.18
- Neurodevelopmental disorder · score 0.12
- Intellectual disability · score 0.11
- apolipoprotein A 1 measurement · score 0.08
- platelet count · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P20933-F1 | alphafold | PREDICTED | 91.70 | — |
Amino-acid sequence (346 residues)
MARKSNLPVL LVPFLLCQAL VRCSSPLPLV VNTWPFKNAT EAAWRALASG GSALDAVESG CAMCEREQCD GSVGFGGSPD ELGETTLDAM IMDGTTMDVG AVGDLRRIKN AIGVARKVLE HTTHTLLVGE SATTFAQSMG FINEDLSTTA SQALHSDWLA RNCQPNYWRN VIPDPSKYCG PYKPPGILKQ DIPIHKETED DRGHDTIGMV VIHKTGHIAA GTSTNGIKFK IHGRVGDSPI PGAGAYADDT AGAAAATGNG DILMRFLPSY QAVEYMRRGE DPTIACQKVI SRIQKHFPEF FGAVICANVT GSYGAACNKL STFTQFSFMV YNSEKNQPTE EKVDCI
Explore N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets